NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Radiopharm Theranostics Limited (RADX) Stock Analysis

Radiopharm Theranostics Limited (RADX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RADX

$2.08

−$0.07 (−3.48%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RADX with… →

RADX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.05
Previous Close
$2.16
Day's Range
2.05–2.15
52-Week Range
2.04–16.25
Volume
7.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.75
Valuation
Market Cap
$30.07M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.85
Financials (FY)
Revenue (FY)
$3.63M+1114.27%
Net Income (FY)
−$38.34M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.46M
1-Year Return
−62.86%
Dividend and dates
Avg Volume
72.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RADX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−60.15%
2025+16.26%
2024 (partial year)−74.59%

As of September 4, 2026.

RADX Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$3.63M−$38.34M−1055.3%
2024$299.23K−$47.95M−16024.3%
2023$292.36K−$34.61M−11838.6%
2022$8.83K−$30.34M−343550.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.63M$39.28K−$34.64M−$38.34M−1055.3%
2024$299.23K$299.23K−$37.17M−$47.95M−16024.3%
2023$292.36K$292.36K−$31.69M−$34.61M−11838.6%
2022$8.83K$8.83K−$19.92M−$30.34M−343550.9%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

RADX Valuation vs Biotechnology Median

Median of 656 stocks
MetricRADXBiotechnology medianvs median
P/S ratio2.2315.260.1x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Radiopharm Theranostics Limited (RADX) carries a market capitalisation of $30.07M. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for RADX is $2.08, dated September 4, 2026. That is −$0.07 (−3.48%) against the previous close. Over the past 52 weeks the price has ranged from $2.04 to $16.25. The latest close sits 1.76% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.63M. Against the prior fiscal year total of $299.23K, that is a change of +1,114.27%. The same year closed with a net loss of $38.34M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −3.85.

Across the 4 fiscal years on file, revenue moves from $8.83K in 2022 to $3.63M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.23. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −62.86%. The stored price history starts on December 5, 2024, and the total return since then is −88.23%. Beta against the wider market is reported at 0.75. Daily returns over the trailing 1 year annualize to a volatility of 168.45%.

Growth & Income

No dividend is on file for RADX.

The record holds one complete calendar year, 2025, which returned +16.26%. 2026 is still running; the price is −60.15% year to date.

Peer Comparison

Radiopharm Theranostics Limited (RADX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Radiopharm Theranostics Limited RADX $30.07M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Radiopharm Theranostics Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Visit website →